Still in the Dark…

#PCWG4 launched #GU26 w/aspirational reliance on #PSMA imaging for drug development

But we will have to acknowledge that #PSMA targeted therapy will likely impact the sensitivity of #PSMA imaging

#PSMAdark
@ascocancer.bsky.social

@melissaabel20 et al
rdcu.be/eKNQe

Still in the Dark…

#PCWG4 launched @ascocancer.bsky.social #GU26 w/aspirational reliance on #PSMA imaging for drug development

But we will have to acknowledge that #PSMA targeted therapy will likely impact the sensitivity of #PSMA imaging

#PSMAdark

@melissaabel20 et al
rdcu.be/eKNQe

We don’t need to fear the Dark in #ProstateCancer

But we will have to acknowledge that #PSMA targeted therapy will likely impact the sensitivity of #PSMA imaging

This likely impacts the desire to use PSMA in restating (still unclear how to do that) & drug development #PSMAdark

As #ESMO25 brings new data on #PSMA it may be time to consider what happens when you target a surface antigen in cancer. How will that impact diagnostic sensitivity of that target?

#PSMAdark
#ProstateCancer #theranostics
Dr Abel et al
@natrevurol.nature.com @ascocancer.bsky.social

rdcu.be/eKNQe